The pharmacotherapeutic management of episodic and chronic migraine with gepants
The small molecule non-peptide calcitonin gene-related peptide (CGRP) receptor antagonists named gepants offer a breakthrough novel approach in migraine acute and prophylactic drug treatment. This review aimed to determine the place of gepants in the treatment of episodic and chronic migraine.The ne...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2023
|
| Sorozat: | EXPERT OPINION ON PHARMACOTHERAPY
24 No. 8 |
| Tárgyszavak: | |
| doi: | 10.1080/14656566.2023.2201375 |
| mtmt: | 33743746 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/26990 |
| Tartalmi kivonat: | The small molecule non-peptide calcitonin gene-related peptide (CGRP) receptor antagonists named gepants offer a breakthrough novel approach in migraine acute and prophylactic drug treatment. This review aimed to determine the place of gepants in the treatment of episodic and chronic migraine.The new-generation gepants are ubrogepant, atogepant, rimegepant and zavegepant. Ubrogepant is ratified for acute migraine treatment, atogepant is validated for preventive therapy, whereas rimegepant is retified for both indications, all via oral administration, while zavegepant is administered intranasally for migraine attacks. Gepants are effective, safe, and well-tolerated in the acute or prophylactic therapy. The PubMed literature search included randomized controlled trials, meta-analyses, real-world data, and review articles published in English until January 2023.Whether gepants will be real game changers in the acute treatment of migraine compared to triptans and ditans, or in the prophylactic therapy compared to standard-of-care preventive drugs or CGRP-targeting monoclonal antibodies can not be answered yet based on the available literature data. |
|---|---|
| Terjedelem/Fizikai jellemzők: | 947-958 |
| ISSN: | 1465-6566 |